© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Induction of Ubiquitin-Conjugating Enzyme by Aggregated Low Density Lipoprotein in Human Macrophages and Its Implications for Atherosclerosis
From the Division of Molecular Hemopoiesis (J.K., Y.F., M.N., M.M.), Center for Molecular Medicine, Jichi Medical School, Tochigi; Katsuta Research Laboratory (J.K.), Hitachi Koki Co, Ltd, Ibaraki; Clinical Laboratories (N.K., A.T., I.S.), Omiya Medical Center, Jichi Medical School, Saitama; the Department of Internal Medicine (A.T.), Makioka City Hospital, Yamanashi; and Omgen Inc (N.H.), Tokyo, Japan.
Correspondence to Yusuke Furukawa, MD, Division of Molecular Hemopoiesis, Center for Molecular Medicine, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi-machi, Kawachi-gun, Tochigi 329-0498, Japan. E-mail furuyu{at}jichi.ac.jp
Abstract—Recently, we have found that aggregated low density lipoprotein (agLDL) inhibits apoptosis of lipid-bearing macrophages, thereby facilitating foam cell formation and atherosclerosis. To clarify the mechanisms by which agLDL inhibits apoptosis of macrophages, we isolated the genes specifically induced by agLDL by using a subtraction-based cloning strategy. One of the cloned genes, termed low density lipoprotein (LDL)-inducible gene (LIG), encodes a human homologue of bovine ubiquitin-conjugating enzyme E2–25K. Although LIG mRNA was ubiquitously expressed among human tissues, including hematopoietic cells, the abundance of transcripts was markedly increased by agLDL treatment in activated monocytes. LIG mRNA expression was not enhanced by nonatherogenic lipoproteins such as native LDL and high density lipoprotein, suggesting a role in atherosclerosis. Polyubiquitination of intracellular proteins was observed in monocytes cultured with agLDL, which coincided with upregulation of LIG. Furthermore, ubiquitin-dependent degradation of p53, an inducer of apoptosis, was accompanied by LIG induction in agLDL-treated monocytes. The antiapoptotic effect of agLDL was abrogated by a specific proteasome inhibitor, which also increased the half-life of p53 in monocytes. These results suggest that LIG contributes to foam cell formation by the suppression of apoptosis of lipid-bearing macrophages through ubiquitination and subsequent degradation of p53.
Key Words: foam cell • apoptosis • subtraction cloning • ubiquitin • p53
This article has been cited by other articles:
 |
|
 |
|
  J. Herrmann, L. O. Lerman, and A. Lerman On to the road to degradation: atherosclerosis and the proteasome Cardiovasc Res, November 14, 2009; (2009) cvp333v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Marfella, C. Di Filippo, M. Portoghese, F. Ferraraccio, B. Crescenzi, M. Siniscalchi, M. Barbieri, C. Bologna, M. R. Rizzo, F. Rossi, et al. Proteasome Activity as a Target of Hormone Replacement Therapy-Dependent Plaque Stabilization in Postmenopausal Women Hypertension, April 1, 2008; 51(4): 1135 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Marfella, C. Di Filippo, M. D'Amico, and G. Paolisso Diabetes, Ubiquitin Proteasome System and Atherosclerotic Plaque Rupture Circ. Res., May 25, 2007; 100(10): e84 - e85. [Full Text] [PDF]
|
|
|
|
|
|
R. Marfella, M. Siniscalchi, M. Portoghese, C. Di Filippo, F. Ferraraccio, C. Schiattarella, B. Crescenzi, P. Sangiuolo, G. Ferraro, S. Siciliano, et al. Morning Blood Pressure Surge as a Destabilizing Factor of Atherosclerotic Plaque: Role of Ubiquitin-Proteasome Activity Hypertension, April 1, 2007; 49(4): 784 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Marfella, M. D'Amico, C. Di Filippo, A. Baldi, M. Siniscalchi, F. C. Sasso, M. Portoghese, O. Carbonara, B. Crescenzi, P. Sangiuolo, et al. Increased Activity of the Ubiquitin-Proteasome System in Patients With Symptomatic Carotid Disease Is Associated With Enhanced Inflammation and May Destabilize the Atherosclerotic Plaque: Effects of Rosiglitazone Treatment J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2444 - 2455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Marfella, M. D'Amico, K. Esposito, A. Baldi, C. Di Filippo, M. Siniscalchi, F. C. Sasso, M. Portoghese, F. Cirillo, F. Cacciapuoti, et al. The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Rosiglitazone Treatment Diabetes, March 1, 2006; 55(3): 622 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Martinet, M. De Bie, D. M. Schrijvers, G. R.Y. De Meyer, A. G. Herman, and M. M. Kockx 7-Ketocholesterol Induces Protein Ubiquitination, Myelin Figure Formation, and Light Chain 3 Processing in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2296 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Saville, A. Sparks, D. P. Xirodimas, J. Wardrop, L. F. Stevenson, J.-C. Bourdon, Y. L. Woods, and D. P. Lane Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo J. Biol. Chem., October 1, 2004; 279(40): 42169 - 42181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann, A. Ciechanover, L. O Lerman, and A. Lerman The ubiquitin-proteasome system in cardiovascular diseases--a hypothesis extended Cardiovasc Res, January 1, 2004; 61(1): 11 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann New kits on the blot--can we microarray the future of atherosclerosis? Cardiovasc Res, November 1, 2003; 60(2): 220 - 222. [Full Text] [PDF]
|
|
|
|
|
|
J. Herrmann, W. D. Edwards, D. R. Holmes Jr, K. L. Shogren, L. O. Lerman, A. Ciechanover, and A. Lerman Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1919 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Stramer, J. R. Cook, M. E. Fini, A. Taylor, and M. Obin Induction of the Ubiquitin-Proteasome Pathway during the Keratocyte Transition to the Repair Fibroblast Phenotype Invest. Ophthalmol. Vis. Sci., July 1, 2001; 42(8): 1698 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Tabas p53 and Atherosclerosis Circ. Res., April 27, 2001; 88(8): 747 - 749. [Full Text] [PDF]
|
|